A team of multidisciplinary scientists – including bioengineers, materials-scientists and immunologists – at the Wyss Institute has created a novel infection vaccine platform know as OmniVax. Technology Networks spoke with Lead Senior Staff Scientist Ed Doherty from the Wyss Institute for Biologically Inspired Engineering at Harvard University, to learn more.
Up to 80% of proteins do not possess binding sites suitable for direct binding of small molecule drugs, making them “undruggable”. To overcome this problem, Anima Biotech has developed a platform to identify drugs with the ability to interfere with the production of these “undruggable” proteins, by selectively inhibiting the translation of mRNA.Read More
Scripps Research spin-off company Ufovax employs the single-component self-assembling protein nanoparticle (1c-SApNP®) platform technology, that was created in the laboratory of Professor Jiang Zhu, to address some of the key challenges in modern vaccine development. We spoke with Dr Colette Saccomanno to learn more.Read More
At a recent London Proteomics Discussion Group Meeting, Professor Roman Fischer kicked off the event by addressing the apparent "failure" of proteomics to deliver new clinical biomarkers thus far. Technology Networks sat down with Fischer to discuss spatial proteomics, and to expand on some of the key aspects of his research.Read More
Technology Networks spoke with Gil Van Bokkelen, CEO of Athersys, to learn more about MultiStem and the main mechanisms of action the cells have on the body. Gil also discussed some of the additional indications that the cells are being investigated as potential therapies for, including ischemic stroke and acute respiratory distress syndrome (ARDS).Read More
To learn more about plasma viscosity and how it can be measured, as well as understand how this information could potentially be used to help diagnose and treat COVID-19 patients, Technology Networks spoke with Bernie Benson, MD of Benson Viscometers.
This article provides tips and tricks for efficient delivery of CRISPR genome editing technology into primary cells and cell lines.Read More
Codexis and Molecular Assemblies recently announced a partnership through which the companies aim to engineer enzymes that will optimize the process of enzymatic DNA synthesis – an alternative approach to chemical DNA synthesis. Technology Networks spoke with Codexis to find out how this will transform the field of DNA synthesis.Read More